Stephen Bagnoli, MD
Pulmonary Disease · Jacksonville, FLNPI 1649270638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 387 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 27.9% of the total. Reporting peaked in 2022 at $1,511 and has fallen 52.4% since, to $719 in 2024.
Across 387 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$581
- Insmed, Inc.$493
- Mylan Specialty L.p.$483
- Grifols USA, LLC$383
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,10798%
- Education$1272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 112 | $2,022 |
| GSK | 71 | $1,193 |
| Boehringer Ingelheim | 34 | $581 |
| Insmed, Inc. | 23 | $493 |
| Mylan Specialty L.p. | 22 | $483 |
| Grifols USA, LLC | 17 | $383 |
| Actelion Pharmaceuticals US, Inc. | 9 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $184 |
| Philips North America LLC | 8 | $158 |
| Regeneron Healthcare Solutions, Inc. | 7 | $138 |
| Sanofi | 6 | $134 |
| Genentech USA, Inc. | 9 | $133 |
| Mallinckrodt Hospital Products Inc. | 5 | $124 |
| Shire North American Group Inc | 4 | $90 |
| Amgen | 6 | $89 |
| Sunovion Pharmaceuticals Inc. | 9 | $84 |
| Electromed, Inc. | 6 | $71 |
| ANI Pharmaceuticals, Inc. | 2 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $62 |
| Jazz Pharmaceuticals Inc. | 3 | $61 |
| Circassia Inc. | 3 | $56 |
| Vifor Pharma, Inc. | 2 | $54 |
| Inogen, Inc. | 3 | $54 |
| Gilead | 3 | $50 |
| Harmony Biosciences LLC | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Pulmonx Corporation | 1 | $40 |
| Eisai Inc. | 1 | $28 |
| Pfizer | 1 | $25 |
| Novartis | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Merck | 1 | $16 |
| Baxter Healthcare | 1 | $14 |
How this compares
$7,234 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $281,366 |
| Spiriva RespimatTiotropium Bromide | 67 | $56,008 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $54,373 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $31,098 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $30,747 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $20,442 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $16,438 |
| Arnuity ElliptaFluticasone Furoate | 27 | $11,798 |
| DuleraMometasone/Formoterol | 23 | $11,018 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $10,613 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $7,903 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,736 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $5,536 |
| Theo-24Theophylline Anhydrous | 12 | $4,953 |
| Roflumilast | 28 | $2,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,193 | $365,622489 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,022 | $78,714118 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $581 | $76,449105 claims |
| MerckDulera | $16 | $11,01823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.